Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
(Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback